Stockscreener 앱 받기
5.39
3.26%
0.17
시간 외 거래:
5.52
0.13
+2.41%
전일 마감가:
$5.22
열려 있는:
$5.42
하루 거래량:
398.38K
Relative Volume:
1.69
시가총액:
$104.61M
수익:
$155.00K
순이익/손실:
$-30.01M
주가수익비율:
-3.5461
EPS:
-1.52
순현금흐름:
$-11.98M
1주 성능:
+4.46%
1개월 성능:
-18.58%
6개월 성능:
-54.13%
1년 성능:
-20.38%
1일 변동 폭
$5.23
$5.42
1주일 범위
$4.81
$5.745
52주 변동 폭
$4.81
$14.74
Inmune Bio Inc Stock (INMB) Company Profile
명칭
Inmune Bio Inc
전화
(858) 964-3720
주소
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-05-24 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-21 | 개시 | B. Riley Securities | Buy |
| 2021-01-22 | 재확인 | Maxim Group | Buy |
| 2020-09-01 | 개시 | BTIG Research | Buy |
| 2020-07-15 | 재확인 | H.C. Wainwright | Buy |
모두보기
Inmune Bio Inc 주식(INMB)의 최신 뉴스
Inmune Bio CFO buys $52,868 in company stock By Investing.com - Investing.com Australia
Analytical Overview: INmune Bio Inc (INMB)’s Ratios Tell a Financial Story - The Dwinnex
INmune Bio Inc [INMB] Investment Guide: What You Need to Know - Knox Daily
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease - The Manila Times
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease - Post Register
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease - StockTitan
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal (NASDAQ:INMB) - Seeking Alpha
CVI Holdings LLC Purchases New Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
CVI Holdings LLC Purchases New Position in INmune Bio, Inc. (NASDAQ:INMB) - MarketBeat
Raymond James Initiates Coverage of INmune Bio (INMB) with Outperform Recommendation - MSN
Achieve, INmune, Lenz stocks win bullish view from RayJay - Seeking Alpha
INmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Raymond James - Defense World
INmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Raymond James - MarketBeat
INmune Bio reports progress in prostate cancer trial By Investing.com - Investing.com Canada
INmune Bio reports progress in prostate cancer trial - Investing.com
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort - The Manila Times
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort - EIN News
UCB rapidly bolsters blockbuster potential for Bimzelx with 3 new FDA approvals - FiercePharma
What is the investor’s view on Immunic Inc (IMUX)? - US Post News
You might want to take a look at Inuvo Inc (INUV) now - SETE News
Imunon Inc (IMNN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Gaining Ground: Universe Pharmaceuticals INC (UPC) Closes Lower at 0.29, Down -13.83 - The Dwinnex
Innate Pharma Advances Novel Cancer Treatment - TipRanks
Century Therapeutics, Inc. (NASDAQ:IPSC) Stake Cut by Federated Hermes Inc. - MarketBeat
Innate Pharma: green light from the FDA for a study - Marketscreener.com
Itau Unibanco Holding S.A. Trims Stock Holdings in Micron Technology, Inc. (NASDAQ:MU) - Defense World
Integrated BioPharma (OTCMKTS:INBP) Posts Quarterly Earnings Results - Defense World
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt (NASDAQ:IBRX) - Seeking Alpha
Mutual of America Capital Management LLC Sells 5,171 Shares of CubeSmart (NYSE:CUBE) - Defense World
INmune Bio stock hits 52-week low at $5.17 amid market challenges By Investing.com - Investing.com South Africa
INmune Bio stock hits 52-week low at $5.17 amid market challenges - Investing.com
How To Trade (INMB) - Stock Traders Daily
Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA - Proactive Investors Australia
You might want to take a look at Imunon Inc (IMNN) now - SETE News
INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com Australia
Raymond Tesi Buys Handful Of Shares In INmune Bio - Simply Wall St
BTIG maintains Buy rating on INmune Bio shares with steady price target - Investing.com Canada
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - Defense World
BTIG maintains Buy rating on INmune Bio shares with steady price target - Investing.com
INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com
Its Stock Has Paid Off Big Time For INmune Bio Inc - SETE News
Market Watch: Immuneering Corp (IMRX)’s Noteworthy Drop, Closing at 2.78 - The Dwinnex
INmune Bio reports strong data from Alzheimer's trial - Investing.com
INmune Bio reports strong data from Alzheimer's trial By Investing.com - Investing.com Canada
INmune Bio reports strong data from Alzheimer's trial - Investing.com India
INmune Bio reports strong data from Alzheimer's trial By Investing.com - Investing.com South Africa
INmune Bio announces results of additional interim analysis of Phase 2 trial - TipRanks
INmune Bio reports strong data from Alzheimer's trial By Investing.com - Investing.com UK
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints - StockTitan
How to interpret INmune Bio Inc (INMB)’s stock chart patterns - US Post News
Inmune Bio Inc (INMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
4.86%
자본화:
|
볼륨(24시간):